vimarsana.com

Latest Breaking News On - Craigb granowitz - Page 1 : vimarsana.com

Sotagliflozin Improved Outcomes in Patients With and

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology s 71st Annual Scientific Session (ACC 22)

02.04.2022 - Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with sotagliflozin treatment as compared to placeboTHE WOODLANDS, Texas, April 02, 2022 . Seite 1

Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update

Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases

News Category Global Banking & Finance Reviews Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.